https://scholars.lib.ntu.edu.tw/handle/123456789/476407
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHEN-CHUNG LIU | en_US |
dc.contributor.author | YI-LING CHIEN | en_US |
dc.contributor.author | MING-HSIEN HSIEH | en_US |
dc.contributor.author | TZUNG-JENG HWANG | en_US |
dc.contributor.author | Hwu H.-G. | en_US |
dc.contributor.author | CHIH-MIN LIU | en_US |
dc.creator | Liu C.-C.;Chien Y.-L.;Ming-Hsien Hsieh;Hwang T.-J.;Hwu H.-G.;Liu C.-M. | - |
dc.date.accessioned | 2020-03-17T06:22:47Z | - |
dc.date.available | 2020-03-17T06:22:47Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/476407 | - |
dc.description.abstract | INTRODUCTION: This study aimed to observe treatment response using aripiprazole for subjects with ultra-high risk (UHR) state of psychosis or at their first-episode psychosis (FEP) who were drug-naive or only have received antipsychotic therapy temporarily. METHODS: All patients received aripiprazole 3.75 mg/d initially to test tolerability and increased to 7.5 mg during the first 2 weeks. A flexible dosing strategy based on clinical improvement and tolerability with a target dose 15 mg/d by the end of the fourth week. Clinical severity was assessed by a Mandarin version of the positive and negative syndrome scale for schizophrenia at baseline, the end of the second and the fourth week. Adverse reactions were recorded by a log, and concomitant medications were allowed. RESULTS: A total of 20 FEP and 11 UHR patients, including 18 drug-naive (11 FEP and 7 UHR) and 13 antipsychotic-short-exposure patients (9 FEP and 4 UHR), participated in and 29 completed the study. Most of them received aripiprazole no more than 7.5 mg/d at end point with favorable response, although many of them reported adverse events. Both UHR and FEP patients got significant decrease of positive symptom scores in a similar pattern. Both groups did not show significant changes in negative symptom scores. CONCLUSION: The treatment response of UHR patients is likely a continuum from that of the FEP patients. Low-dose aripiprazole revealed potential efficacy for patients with less severe psychopathology, at putative prodromal or early state of psychosis, yet still was accompanied by adverse events while treating this mostly drug-naive population. Copyright ? 2013 Lippincott Williams &Wilkins. | - |
dc.relation.ispartof | Journal of Clinical Psychopharmacology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | aripiprazole; adolescent; adult; adverse outcome; anxiety; article; diarrhea; disease severity; drug dose increase; drug safety; drug tolerability; female; gastrointestinal symptom; headache; high risk patient; human; indigestion; major clinical study; male; motor retardation; nausea; open study; parkinsonism; priority journal; psychosis; rating scale; restlessness; side effect; somnolence; treatment response; tremor; unspecified side effect; weakness; Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | - |
dc.title | Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: An open-label study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1097/JCP.0b013e31827cb017 | - |
dc.identifier.pmid | 23277261 | - |
dc.identifier.scopus | 2-s2.0-84873094956 | - |
dc.relation.pages | 18-23 | - |
dc.relation.journalvolume | 33 | - |
dc.relation.journalissue | 1 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Center for Artificial Intelligence and Advanced Robotics | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Brain and Mind Sciences | - |
crisitem.author.dept | Neurobiology and Cognitive Science Center | - |
crisitem.author.dept | Center for Integrated Dementia Care | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Brain and Mind Sciences | - |
crisitem.author.orcid | 0000-0002-9290-110X | - |
crisitem.author.orcid | 0000-0002-3477-3015 | - |
crisitem.author.orcid | 0000-0002-3585-7843 | - |
crisitem.author.orcid | 0000-0001-7894-9484 | - |
crisitem.author.orcid | 0000-0001-7016-8990 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。